Large-scale compounding of semaglutide and tirzepatide was allowed mainly because the FDA listed them as in shortage. Those shortages have resolved, so broad, high-volume compounding is now heavily restricted. Some limited, patient-specific compounding by a licensed pharmacy may still occur in narrow, legitimate cases, but the legal space for it has shrunk. Meanwhile, unregulated "research peptide" and overseas sellers were never legitimate and carry serious counterfeit and safety risks. Because these rules are actively changing, confirm the current status with the FDA and discuss options with your clinician.
Key takeaways
- Compounding boomed under a shortage exception — not because copying GLP-1s was broadly legal.
- With the shortages resolved, broad compounding has become legally restricted and regulators have moved to limit it further.
- Limited, legitimate compounding may still happen via licensed pharmacies in specific circumstances.
- Unregulated "research peptide" sellers are a different, riskier category — counterfeit and contamination dangers are real.
What "compounded" actually means
Compounding is when a licensed pharmacy prepares a customized medication for a patient — for example, when someone needs a different strength or can't tolerate an ingredient in the commercial product. It's a legitimate, long-standing part of pharmacy. The controversy with GLP-1s isn't compounding itself; it's whether pharmacies could produce large volumes of copies of expensive brand-name drugs like Ozempic and Zepbound, and sell them widely at a fraction of the price.
The answer hinges on a specific rule in U.S. law: compounders generally can't just make copies of a commercially available, FDA-approved drug. One of the main exceptions is when that drug is officially in shortage. That single exception is the whole story of the compounded-GLP-1 boom — and its unwinding.
Why the compounding rules changed
When demand for GLP-1s exploded, the manufacturers couldn't keep up, and the FDA formally listed semaglutide and tirzepatide as being in shortage. That triggered the exception, and compounding pharmacies — plus a wave of telehealth platforms built around them — began supplying compounded versions at scale. For a while, it was one of the cheapest ways to get a GLP-1.
Then supply caught up. The FDA determined the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. Once a drug comes off the shortage list, the legal basis for broadly compounding copies of it falls away. Regulators then set enforcement timelines, and in 2026 the FDA moved further — proposing to exclude semaglutide, tirzepatide and liraglutide from the list of bulk ingredients that large "503B" outsourcing facilities may use, citing no clinical need. Industry groups challenged these moves in court, but requests to pause them were denied, so the tightening held. The direction of travel is clear: the easy, high-volume compounding era is ending.
| Milestone | What happened |
|---|---|
| Shortage era | GLP-1s listed in shortage; large-scale compounding permitted under the shortage exception |
| Tirzepatide shortage resolved | FDA determined the shortage resolved in October 2024 |
| Semaglutide shortage resolved | FDA determined the shortage resolved in February 2025 |
| 2026 restriction | FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk-ingredient list, citing no clinical need |
So are compounded GLP-1s legal now?
The honest answer is "much less than they were, and it's still shifting." Broad, high-volume compounding of copies is no longer supported now that the shortages have resolved. That said, compounding law is nuanced: a licensed pharmacy may still prepare a patient-specific product in narrower, legitimate circumstances — for instance, a documented clinical need that the commercial product doesn't meet. What has clearly gone away is the "order a cheaper copy online because everyone's doing it" model that defined the boom.
Because the details — enforcement dates, court rulings, exactly what remains permitted — are genuinely moving, this is one topic where you shouldn't rely on a static article (including this one) for the fine print. Check the FDA's own compounding pages for the current status, and talk to your clinician or pharmacist about legitimate ways to access an approved product. Our cost and insurance guide and how to get a prescription guide cover the above-board routes.
Are compounded GLP-1s safe — and how to spot a risky source
Safety depends almost entirely on where the product comes from. A compounded drug made by a properly licensed U.S. pharmacy, for a specific patient, with a valid prescription from a licensed prescriber, sits in a regulated system with accountability. That is a completely different thing from the unregulated corner of the market — "research peptides," vials labeled "not for human use," and overseas grey-market sellers — which operates outside FDA oversight entirely.
The FDA has received hundreds of adverse-event reports tied to compounded GLP-1s, a notable share involving dosing errors where patients drew the wrong amount out of a multidose vial. Add the risks of counterfeit or contaminated product from unregulated sellers, and the stakes are real. If you're evaluating any non-brand source, use the checklist below.
Frequently asked questions
Are compounded GLP-1s legal in 2026?
Large-scale compounding was permitted mainly while the FDA listed these drugs as in shortage. Those shortages have resolved, so broad compounding is now heavily restricted. Limited, patient-specific compounding by a licensed pharmacy may still occur in specific cases, but the legal room has narrowed. Verify current status with the FDA.
Why did the compounding rules change?
U.S. law lets compounders copy a commercial drug mainly when it's in shortage. During the GLP-1 shortages that allowed large-scale compounding. As manufacturers caught up and the FDA removed semaglutide and tirzepatide from the shortage list, the legal basis fell away and regulators moved to restrict it further.
Are compounded GLP-1s safe?
It depends on the source. A product from a licensed U.S. pharmacy for a specific patient is very different from an unregulated "research peptide" or overseas seller. The FDA has received adverse-event reports tied to compounded GLP-1s, including dosing errors from multidose vials, and unregulated sources carry counterfeit and contamination risks.
How do I tell a legitimate source from a risky one?
Look for a licensed U.S. pharmacy and a real prescription from a licensed U.S. prescriber after an actual medical evaluation. Avoid anything sold as a "research peptide," "not for human use," from overseas grey-market sites, or priced too good to be true. When unsure, ask your clinician and confirm the pharmacy's licensing.
Sources & further reading
- U.S. Food & Drug Administration — statements and guidance on compounding of GLP-1 drugs and the resolution of the semaglutide and tirzepatide shortages; FDA drug shortage database.
- U.S. Food & Drug Administration — adverse event reporting related to compounded GLP-1 products.
- FDA guidance on 503A pharmacy compounding and 503B outsourcing facilities.